Mycophenolate Mofetil Is Effective and Well Tolerated in the Treatment of Refractory Acute and Chronic Graft-versus-Host Disease

被引：0
作者：
Akiyoshi Takami
Kanako Mochizuki
Hirokazu Okumura
Hirohito Yamazaki
Masahide Yamazaki
Yukio Kondo
Hidesaku Asakura
Shinji Nakao
Satsuki Ito
Yukio Suga
机构：
[1] Kanazawa University Graduate School of Medicine,Department of Cellular Transplantation Biology
[2] Kanazawa University Graduate School of Medicine,Department of Pharmacy
来源：
International Journal of Hematology | 2006年 / 83卷
关键词：
Mycophenolate mofetil; Allogeneic stem cell transplantation; Mismatched donor; Graft-versus-host disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
We enrolled 11 patients with refractory graft-versus-host disease (GVHD) in a prospective trial evaluating the efficacy of mycophenolate mofetil (MMF). Four (67%) of the 6 patients with acute GVHD and all 5 patients with chronic GVHD responded to MMF. Ten (91%) of the 11 patients were able to decrease steroid use (median decrease, 86%; range, 25%-100%). After a median follow-up of 18 months (range, 1-65 months), 7 patients (64%) remained alive. The adverse events were infectious complications (36%), diarrhea (27%), and neutropenia (18%); the only patient discontinuing MMF did so because of grade 4 neutropenia. This preliminary study suggests that MMF is a well-tolerated agent and has a beneficial effect in the treatment of refractory acute and chronic GVHD.
引用
收藏
页码：80 / 85
页数：5
相关论文
共 96 条
[1]  
Martin PJ(1991)A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment Blood. 77 1821-1828
[2]  
Schoch G(2000)Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities Bone Marrow Transplant 26 985-991
[3]  
Fisher L(2000)Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease Biol Blood Marrow Transplant. 6 613-620
[4]  
Furlong T(1988)Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease Blood. 72 555-561
[5]  
Storb R(1989)Predictors of death from chronic graft-versus-host disease after bone marrow transplantation Blood. 74 1428-1435
[6]  
Anasetti C(2005)Novel strategies for steroid-refractory acute graft-versus-host disease Curr Opin Hematol. 12 40-44
[7]  
Carnevale-Schianca F(2004)Graft-versus-host disease: how to translate new insights into new therapeutic strategies Biol Blood Marrow Transplant. 10 815-825
[8]  
Martin P(2004)Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease Biol Blood Marrow Transplant. 10 655-668
[9]  
Sullivan K(2004)Diagnosis and clinical management of chronic graft-versus-host disease Int J Hematol. 79 221-228
[10]  
Sullivan KM(2004)Chronic graft-versus-host disease: clinical features and grading systems Int J Hematol. 79 216-220
12345678910